Women with platinum resistant ovarian cancer who have a measurable disease and have received 5 or less previous lines of therapy may be eligible to participate in this study. This treatment, which will assess the combination of the study drug, VB-11, and paclitaxel in patients with platinum resistant ovarian cancer, will be led by Dr. Joshua Cohen and his dynamic research team from the UCLA Department of Obstetrics and Gynecology
Participants must meet the following criteria:
If you've answered yes to all of the above questions, please
Email: email@example.com or Call: 310-267-4331.
Patients will be stratified by the following:
All participants enrolled in the study will undergo the following testing:
Once in the study, during the 1stvisit, participants will be randomized (like drawing numbers from a hat) to one of the 2 treatment groups (study drug + paclitaxel or placebo + paclitaxel). As this is a placebo-controlled study, please note that you may receive inactive medications.
UCLA Protocol ID: IRB# 19-001886.
Please call (310) 794-9652 to learn more. In order to protect your privacy, please do not include any personal health information if you choose to e-mail us.
Learn more at UCLAHealth Clinical Trials >